Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Replication of the NefIgArd Trial of Effectiveness and Safety of a Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

NCT06589752 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06589752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06589752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Replication of the NefIgArd Trial of Effectiveness and Safety of a Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Completed
Start date
April 24, 2023
Completion date
September 5, 2024
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary iga nephropathy